key: cord-0748402-oqxgf77e authors: Huh, Kyungmin; Ji, Wonjun; Kang, Minsun; Hong, Jinwook; Hwan, Gi; Lee, Rugyeom; Na, Yewon; Jung, Jaehun title: Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea date: 2020-12-19 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.12.041 sha: 6c5cd2e0d7e93edb8e63687cbb8bb4bd60eb1032 doc_id: 748402 cord_uid: oqxgf77e OBJECTIVES: Concerns have been expressed that some drugs may increase susceptibility to SARS-CoV-2 infection. In contrast, other drugs have generated interest as potential therapeutic agents. METHODS: All adults aged ≥18 years who were tested for COVID-19 were included. Exposure was defined as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19 or later. The outcome measures were the diagnosis of COVID-19 and severe COVID-19. Disease risk score matching and multiple logistic regression was used. RESULTS: Matched claims and testing results were available for 219,961 subjects, of whom 7,341 (3.34%) were diagnosed with COVID-19. Patients were matched to 36,705 controls, and the subset of 878 patients of severe COVID-19 also matched with 1,927 mild-to-moderate patients. Angiotensin receptor blockers were not associated with either the diagnosis of COVID-19 (adjusted OR [aOR], 1.02; 95% confidence interval [CI], 0.90–1.15) or severe disease (aOR, 1.11; 95% CI, 0.87–1.42). The use of hydroxychloroquine was not associated with a lower risk for COVID-19 (aOR, 0.94; 95% CI, 0.53–1.66) or severe disease (aOR, 3.51; 95% CI, 0.76–16.22). CONCLUSIONS: In this national claims data-based case-control study, no commonly prescribed medications were associated with risk for COVID-19 infection or severity. Coronavirus disease (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has spread worldwide since the first reported case in late 2019. Host cell entry of SARS-CoV-2 requires angiotensin-converting enzyme 2 (ACE2) (Hoffmann et al., 2020) . The action of ACE2 is not directly affected by ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), although these drugs The possible association of commonly used drugs with the risk of COVID-19, and on its severity level, is a particularly important issue. However, it is virtually impossible to design a prospective clinical trial on medications taken before a diagnosis of COVID-19. On the other hand, results from randomized clinical trials using drugs with potential therapeutic effects are being published (Beigel et al., 2020 , Pan et al., 2020 . Still, most of these trials were designed J o u r n a l P r e -p r o o f to study the effect of the drugs after a diagnosis and their effectiveness as prophylaxis or early treatment is yet to be tested thoroughly. Therefore, controversy persists regarding possible benefits or harm that may be associated with use of various drugs for patients with In the absence of prospective clinical data, carefully curated and reliable data from a large cohort may be a useful alternative. Thus, we used nationwide medical insurance claims data and records of confirmed COVID-19 patients to evaluate the relationships between common medications prescribed prior to COVID-19 testing and the risk for and severity of in South Korea. We conducted a retrospective case-control study using information extracted from two national Korean databases. The Korean Health Insurance Review & Assessment Service (HIRA) is a quasi-governmental agency that reviews all claims made to the National Health Insurance Service, the universal single payer for healthcare in Korea. All reimbursement claims for COVID-19 tests in suspected cases are sent for review by the HIRA (Supplementary figure 1). Claims for COVID-19 tests are made using a special "public crisis" code (MT043) and can thus identify all individuals tested for COVID-19 in Korea. Eligible subjects were all individuals ≥18 years old with an MT043 code. Patients were identified by matching this list with data from the Korea Centers for Disease Control and evaluated based on the numbers of claims for hospitalizations, outpatient visits, and emergency room visits within 1 year before the tests for COVID-19. As the likelihoods of being tested for COVID-19, of testing positive, and of undergoing a severe clinical course are all affected by demographic characteristics and comorbidities, we used disease risk score (DRS) matching to control for discrepancies of baseline characteristics. DRS models were constructed to estimate the propensity for outcome measures with age, sex, coverage for low household income, CCI, and comorbidities (diabetes, hypertension, asthma/allergic rhinitis, chronic heart diseases, chronic lung diseases, malignancy, chronic kidney diseases and chronic neurologic diseases) as covariates. Each case of COVID-19 was matched with up to five controls by greedy matching algorithms; each case of severe COVID-19 was matched with up to three controls with mild-to-moderate COVID-19 (Stuart, 2010) . A sensitivity analysis was conducted with the prescription of medications that was continued up to 14 days or less, instead of 7 days or less, before COVID-19 testing as exposure. The baseline demographic characteristics and comorbidities of patients and controls were compared using the χ 2 test, Fisher's exact test or Student's t test, as appropriate. Exposures to the drugs of interest were compared between DRS-matched groups using multivariable logistic regression models with sex, age, region of residence, comorbidities, healthcare utilization, and other drugs of interest as covariates. All tests were two-tailed and results were considered statistically significant at P values <0.05. All analyses were performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA). We identified 219,961 patients who had been tested for COVID-19, including 7,341 patients (3.34%) who were subsequently diagnosed with COVID-19 ( Figure 1 Figure 2A and Table 3 ). No significant associations were observed with any of the combinations. In contrast, the prescription of non-steroid anti-inflammatory drugs (NSAIDs) was identified as an independent risk factor for severe disease among persons infected with SARS-CoV-2 Following a literature review, the following drugs were selected as having potential therapeutic effects: HCQ, camostat, ciclesonide, azithromycin, sirolimus, mycophenolate, and amiodarone ( Figure 2B and Table 3 ). Lopinavir/ritonavir and other protease inhibitors, direct antiviral agents for hepatitis C, and tocilizumab were excluded from the analysis as the numbers of prescriptions for those agents were too small. The use of HCQ was not associated with the risk of COVID-19 infection (aOR, 0.94; 95% CI, 0.53-1.66; P=0.82) or with severe disease (aOR, 3.51; 95% CI, 0.76-16.22; P=0.11). Azithromycin also did not show an association with infection (aOR, 0.58; 95% CI, 0.30-1.12; P=0.10) or severe disease (aOR, 2.03; 95% CI, 0.39-10.60; P=0.40). A lack of significant associations was also observed for camostat, ciclesonide, sirolimus, mycophenolate, and amiodarone. J o u r n a l P r e -p r o o f Sensitivity analysis was conducted using an alternative definition of exposure: the prescription of drugs that was continued up to 14 days or less prior to test for COVID-19 (Supplementary Table 4 ). The results were generally consistent with the main analysis with some exceptions. NSAIDs were associated with an increased risk for COVID-19 diagnosis (aOR, 1.10; 95% CI, 1.03-1.18; P=0.006); however, chronic use (≥30 days within the last 90 days) was associated with a lower risk (aOR, 0.76; 95% CI, 0.68-0.86; P<0.001), which was similar to their association with severity. Ciclesonide (aOR, 6.01; 95% CI, 1.01-35.59; P=0.05) and mycophenolate (aOR, 0.37; 95% CI, 0.14-0.95, P=0.04) showed statistically significant associations. Using Korean health insurance claims and SARS-CoV-2 testing results, this large casecontrol study found that none of the drugs commonly used to treat chronic conditions were associated with the risk for COVID-19 or its severity. ACEIs and ARBs inhibit the activity of ACE1, which is a homolog to ACE2 but is not used by SARS-CoV for host cell entry We also observed a lack of association with other medications commonly used for diabetes and dyslipidemia, namely metformin, thiazolidinediones, and statins. Our results suggest that those drugs could be safely continued without increasing the risk of COVID-19 or of severe disease. There has been a brief controversy that the use of NSAIDs might increase the risk of severe COVID-19 (Little, 2020) . We also observed that the prescription of NSAIDs was associated with a higher risk of severe COVID-19, albeit the risk of an overall COVID-19 diagnosis was not higher in patients taking NSAIDs. In our post-hoc analysis, the chronic use of NSAIDs (≥30 days within 90 days prior to testing) was not shown to increase the risk for severe COVID-19, while a new prescription within 7 days prior to testing did increase risk. Our finding suggests that NSAID use might indicate the presence of symptoms severe enough to require pharmaceutical intervention; it seems unlikely that NSAIDs would directly increase the risk for severe disease among patients with COVID-19. A recent multicenter retrospective cohort study of hospitalized patients with COVID-19 also reported a lack of association between the pre-hospital use of NSAIDs and mortality (Imam et al., 2020) . Chloroquine (CQ) has been used to treat malaria since the 1940s and has also been used for Ciclesonde and mycophenolate were shown to be associated with the diagnosis of COVID-19 in the sensitivity analysis only. As the sensitivity analysis used a less stringent definition of exposure, we suggest its result be interpreted carefully. Further studies are needed to reach a firm conclusion regarding the two drugs. Our study has several strengths. First, South Korea rapidly established a large testing capacity and has successfully contained the SARS-CoV-2 outbreak, suggesting that it is unlikely that a large number of COVID-19 patients were missed. Also, we were able to use "test-negative" controls owing to the vast testing capacity. Second, the single-payer universal healthcare system in Korea ensures that we had reliable data on medication use and comorbidities. Given that there is near-complete coverage of common illnesses in the HIRA database, only an extremely small proportion of patients would not have data on the drugs of interest. The comprehensiveness of our datasets enabled the use of DRS matching to mitigate differences in baseline characteristics. Finally, our methods are transparent, and the results are reproducible. The HIRA dataset we used are available for public analysis and our full coding protocol is included in the Supplements. The present study does have several limitations. First, many of the drugs proposed for treatment of COVID-19 are not prescribed frequently enough to provide sufficient statistical power for analysis despite the large size of overall study population. Second, the use of claims data precludes an analysis of prescription compliance or the accuracy of comorbidity diagnoses. Also, over-the-counter use of drugs could not be captured. While all other study drugs require prescription in Korea, NSAIDs use might be underestimated in our study. Third, we could not obtain data regarding the severity of the underlying conditions, performance status, and socioeconomic characteristics as this information was not available in the HIRA or KCDC databases. Finally, the differences in baseline characteristics between groups remained after DRS-matching, albeit in a substantially smaller degree. While we tried to further adjust for those variables using logistic regression, the possibility of residual confounding cannot be excluded. In conclusion, we found no association between drugs of concern, including ARB and HCQ, and the risk of COVID-19 and its severity. Our results are reassuring that drugs commonly used for chronic conditions do not increase the risk for COVID-19. However, our findings also suggest that repurposing pharmaceutical agents may not provide significant clinical benefits for patients with COVID-19. Clinical trials are needed to generate high-quality evidence regarding the efficacy of these agents. Author contributions. Drs. Huh and Jung had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Medical Center (grant nos. 2018-17 and 2019-11). The sponsor of the study was not involved in the study design, analysis, and interpretation of data; writing of the report; or the decision to submit the study results for publication. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. J o u r n a l P r e -p r o o f Amiodarone as a possible therapy for coronavirus infection Addresses Concerns Re: Using RAAS Antagonists in COVID-19 Remdesivir for the Treatment of Covid-19 -Final Report Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus Susceptibility of different eukaryotic cell lines to SARS-coronavirus SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Non-steroidal anti-inflammatory drugs and covid-19 Evaluation of Ebola Virus Inhibitors for Drug Repurposing Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2 No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Zika virus cell tropism in the developing human brain and inhibition by azithromycin Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Matching methods for causal inference: A review and a look forward The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms